UNITY Biotechnology Inc
UBX0.200USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
3.44MMarket Cap
LossP/E TTM
More Details of UNITY Biotechnology Inc Company
Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence and is advancing senolytic programs primarily in ophthalmologic disorders. In addition, it has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1967 is its back-up compound to UBX1325. UBX2089, an α-Klotho hormone drug candidate, which is being researched for multiple neurology indications.
UNITY Biotechnology Inc Info
Ticker SymbolUBX
Company nameUNITY Biotechnology Inc
IPO dateMay 03, 2018
CEO- -
Number of employees16
Security typeEquity Cash Option
Fiscal year-endMay 03
Address285 East Grand Avenue
CitySOUTH SAN FRANCISCO
Stock exchangeEurex
CountryUnited States of America
Postal code94080
Phone16504161192
Websitehttps://unitybiotechnology.com/
Ticker SymbolUBX
IPO dateMay 03, 2018
CEO- -
Company Executives of UNITY Biotechnology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Craig R. Jalbert
Mr. Craig R. Jalbert
President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Corporate Secretary, Director
President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Corporate Secretary, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Craig R. Jalbert
Mr. Craig R. Jalbert
President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Corporate Secretary, Director
President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Corporate Secretary, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ghosh (Anirvan)
0.80%
Mayo Clinic
0.72%
Sullivan (Lynne Marie)
0.42%
Nguyen (Alexander Hieu)
0.21%
XTX Markets LLC
0.08%
Other
97.77%
Shareholders
Shareholders
Proportion
Ghosh (Anirvan)
0.80%
Mayo Clinic
0.72%
Sullivan (Lynne Marie)
0.42%
Nguyen (Alexander Hieu)
0.21%
XTX Markets LLC
0.08%
Other
97.77%
Shareholder Types
Shareholders
Proportion
Individual Investor
1.43%
Endowment Fund
0.72%
Venture Capital
0.08%
Investment Advisor
0.08%
Research Firm
0.01%
Other
97.68%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
78
1.99M
11.56%
-2.01M
2025Q2
89
3.22M
18.71%
-1.65M
2025Q1
97
3.46M
20.17%
-1.23M
2024Q4
105
3.52M
20.91%
-1.73M
2024Q3
123
3.68M
21.86%
-2.33M
2024Q2
132
4.12M
53.35%
-2.10M
2024Q1
133
4.24M
54.22%
-1.90M
2023Q4
140
4.96M
58.51%
+317.31K
2023Q3
176
3.32M
51.30%
-1.44M
2023Q2
196
3.34M
51.73%
-2.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ghosh (Anirvan)
138.45K
0.8%
--
--
Jul 25, 2025
Mayo Clinic
124.08K
0.72%
--
--
Sep 30, 2024
Sullivan (Lynne Marie)
72.30K
0.42%
--
--
Jul 25, 2025
Nguyen (Alexander Hieu)
35.31K
0.21%
--
--
Jul 25, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 19, 2022
Merger
10→1
Oct 19, 2022
Merger
10→1
Oct 19, 2022
Merger
10→1
Oct 19, 2022
Merger
10→1
Date
Type
Ratio
Oct 19, 2022
Merger
10→1
Oct 19, 2022
Merger
10→1
Oct 19, 2022
Merger
10→1
Oct 19, 2022
Merger
10→1
FAQs
Who are the top five shareholders of UNITY Biotechnology Inc?
The top five shareholders of UNITY Biotechnology Inc are:
Ghosh (Anirvan) holds 138.45K shares, accounting for 0.80% of the total shares.
Mayo Clinic holds 124.08K shares, accounting for 0.72% of the total shares.
Sullivan (Lynne Marie) holds 72.30K shares, accounting for 0.42% of the total shares.
Nguyen (Alexander Hieu) holds 35.31K shares, accounting for 0.21% of the total shares.
Ghosh (Anirvan) holds 138.45K shares, accounting for 0.80% of the total shares.
Mayo Clinic holds 124.08K shares, accounting for 0.72% of the total shares.
Sullivan (Lynne Marie) holds 72.30K shares, accounting for 0.42% of the total shares.
Nguyen (Alexander Hieu) holds 35.31K shares, accounting for 0.21% of the total shares.
What are the top three shareholder types of UNITY Biotechnology Inc?
The top three shareholder types of UNITY Biotechnology Inc are:
Ghosh (Anirvan)
Mayo Clinic
Sullivan (Lynne Marie)
Ghosh (Anirvan)
Mayo Clinic
Sullivan (Lynne Marie)
How many institutions hold shares of UNITY Biotechnology Inc (UBX)?
As of 2025Q3, 78 institutions hold shares of UNITY Biotechnology Inc, with a combined market value of approximately 1.99M, accounting for 11.56% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.16%.
What is the biggest source of revenue for UNITY Biotechnology Inc?
In --, the -- business generated the highest revenue for UNITY Biotechnology Inc, amounting to -- and accounting for --% of total revenue.
